Efficacy of Berberine in Patients with Non-Alcoholic Fatty Liver Disease
Tóm tắt
Từ khóa
Tài liệu tham khảo
NM de Alwis, 2008, Non-alcoholic fatty liver disease: the mist gradually clears, J Hepatol, 48, S104, 10.1016/j.jhep.2008.01.009
GC Farrell, 2006, Nonalcoholic fatty liver disease: from steatosis to cirrhosis, Hepatology, 43, S99, 10.1002/hep.20973
QM Anstee, 2013, Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis, Nat Rev Gastroenterol Hepatol, 10, 330, 10.1038/nrgastro.2013.41
LA Adams, 2009, NAFLD as a risk factor for the development of diabetes and the metabolic syndrome: an eleven-year follow-up study, Am J Gastroenterol, 104, 861, 10.1038/ajg.2009.67
R Belfort, 2006, A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis, N Engl J Med, 355, 2297, 10.1056/NEJMoa060326
AJ Sanyal, Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis, N Engl J Med, 362, 1675, 10.1056/NEJMoa0907929
GP Aithal, 2008, Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis, Gastroenterology, 135, 1176, 10.1053/j.gastro.2008.06.047
J Yin, 2008, Efficacy of berberine in patients with type 2 diabetes mellitus, Metabolism, 57, 712, 10.1016/j.metabol.2008.01.013
W Kong, 2004, Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins, Nat Med, 10, 1344, 10.1038/nm1135
J Cameron, 2008, Berberine decreases PCSK9 expression in HepG2 cells, Atherosclerosis, 201, 266, 10.1016/j.atherosclerosis.2008.02.004
SS Lu, 2009, Berberine promotes glucagon-like peptide-1 (7–36) amide secretion in streptozotocin-induced diabetic rats, Journal of Endocrinology, 200, 159
WJ Kong, 2009, Berberine reduces insulin resistance through protein kinase C-dependent up-regulation of insulin receptor expression, Metabolism: Clinical and Experimental, 58, 109, 10.1016/j.metabol.2008.08.013
Y Zhang, 2008, Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine, J Clin Endocrinol Metab, 93, 2559, 10.1210/jc.2007-2404
RJ Perry, 2014, The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes, Nature, 510, 84, 10.1038/nature13478
X Chang, 2010, Berberine reduces methylation of the MTTP promoter and alleviates fatty liver induced by a high-fat diet in rats, J Lipid Rese, 51, 2504, 10.1194/jlr.M001958
LS Szczepaniak, 2005, Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population, Am J Physiol Endocrinol Metab, 288, E462, 10.1152/ajpendo.00064.2004
GC Farrell, 2007, Guidelines for the assessment and management of nonalcoholic fatty liver disease in the Asia-Pacific region: executive summary, J Gastroenterol Hepatol, 22, 775, 10.1111/j.1440-1746.2007.05002.x
E. Cho, 1990, Berberini hydrochloride, in Pharmacopoeia of the People’s Republic of China, 2, 437
A Astrup, 2012, Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide, Int J Obes (Lond), 36, 843, 10.1038/ijo.2011.158
XS Tan, 2013, Tissue distribution of berberine and its metabolites after oral administration in rats, PLoS One, 8, e77969, 10.1371/journal.pone.0077969
H Bian, 2011, Increased liver fat content and unfavorable glucose profiles in subjects without diabetes, Diabetes Technol. Ther, 13, 149, 10.1089/dia.2010.0101
JY Ma, 2013, Excretion of berberine and its metabolites in oral administration in rats, J Pharm Sci, 102, 4181, 10.1002/jps.23718
R Belfort, 2006, A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis, N Engl J Med, 355, 2297, 10.1056/NEJMoa060326
M Takihata, 2013, Comparative study of sitagliptin with pioglitazone in Japanese type 2 diabetic patients: the COMPASS randomized controlled trial, Diabetes Obes Metab, 15, 455, 10.1111/dom.12055
W Chen, 2011, Bioavailability study of berberine and the enhancing effects of TPGS on intestinal absorption in rats, Aaps Pharmscitech, 12, 705, 10.1208/s12249-011-9632-z
W Hua, 2007, Determination of berberine in human plasma by liquid chromatography-electrospray ionization-mass spectrometry, J Pharm Biomed Anal, 44, 931, 10.1016/j.jpba.2007.03.022
W Xie, 2011, Effects and action mechanisms of berberine and Rhizoma coptidis on gut microbes and obesity in high-fat diet-fed C57BL/6J mice, PLoS One, 6, e24520, 10.1371/journal.pone.0024520
YT Liu, 2010, Extensive intestinal first-pass elimination and predominant hepatic distribution of berberine explain its low plasma levels in rats, Drug Metab Dispos, 38, 1779, 10.1124/dmd.110.033936
J Liu, 2011, Tissue distribution of 4 alkaloids of Compound Matrine Injection in rats, Pharmacology and Clinics of Chinese Materia Medica, 27, 74
K Lee, 2011, Mitochondrial carnitine palmitoyltransferase 1a (CPT1a) is part of an outer membrane fatty acid transfer complex, J Biol Chem, 286, 25655, 10.1074/jbc.M111.228692
E Reiling, 2009, Combined effects of single-nucleotide polymorphisms in GCK, GCKR, G6PC2 and MTNR1B on fasting plasma glucose and type 2 diabetes risk, Diabetologia, 52, 1866, 10.1007/s00125-009-1413-9
YS Lee, 2006, Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states, Diabetes, 55, 2256, 10.2337/db06-0006